Interstitial fluid

This medication is not intended to replace foundational GDMT, rather to be utilized in patients experiencing WHF to reduce the risk of CV death or HHF.

#medsky #cardiosky #nursesky

In the VICTORIA-HF trial there was reduction in cardiovascular death and hospitalization for HF.

But remember, WHF may not present solely in the hospital, clinic patients who present with volume overload requiring IV diuretics in the outpatient setting also should be considered.

✔️ Consider addition of vericiguat based on VICTORIA-HF trial data to help reduce mortality

✔️ Referral to advanced heart failure

#medsky #nursesky #cardiosky

We must treat patients with WHF with the extreme urgency that their risk demands.

What can we do?

✔️ Rapid diuresis to relieve symptoms of congestion

✔️ Rapid multi-agent initiation of GDMT or optimization of existing agents

✔️ Remember every touchpoint with a HF patient is an opportunity to evaluate their regimen and make adjustment

#medsky #nursesky #cardiosky @americanheart.bsky.social @accintouch.bsky.social @hfsa.bsky.social

✔️ Don't be paralyzed by fear of end-organ dysfunction, remember untreated or under-treated HF leads to end-organ failure and death
✔️ GDMT is proven safe and effective in these patients with multiple trials and large patient populations

What can we do?
✔️ Avoid delays in therapy - consider multiple agent initiation by starting more than 1 class concurrently
✔️ Initiate therapy when patients are hospitalized - patients who leave the hospital with appropriate therapy in hand are more likely to be adherent

Looking at data from the EVOLUTION-HF trial displayed here the majority of HF patients after 1 year of initiation of GDMT were on sub-optimal dosing (target dosing delineated by dark green).

✔️ Remember every touchpoint with a HF patient is an opportunity to evaluate their regimen and make adjustment

#medsky #nursesky @accintouch.bsky.social @hfsa.bsky.social @thebhf.bsky.social @americanheart.bsky.social

✔️ Don't be paralyzed by fear of end-organ dysfunction, remember untreated or under-treated HF leads to end-organ failure and death
✔️ GDMT is proven safe and effective in these patients with multiple trials and large patient populations

What can we do?
✔️ Avoid delays in therapy - consider multiple agent initiation by starting more than 1 class concurrently
✔️ Initiate therapy when patients are hospitalized - patients who leave the hospital with appropriate therapy in hand are more likely to be adherent

Looking at data from the EVOLUTION-HF trial displayed here the majority of HF patients after 1 year of initiation of GDMT were on sub-optimal dosing (target dosing delineated by dark green).

I really can't stand him